Growth hormone treatment and development of malignancy: recombinant human growth hormone does not induce leukemia in AKR/O-mice.
In 1988 several reports described leukemia in former/present growth hormone (GH)-treated children, and a doubled incidence of leukemia in GH-treated children was concluded in a workshop in Bethesda. A mouse strain (AKR/O) with a high incidence of leukemia was used as a model. AKR/O-mice in the preleukemic adult age and younger mice during rapid growth were treated with recombinant human GH (rhGH) in human therapeutic doses to see whether this treatment would affect the time and presentation of malignant disease. The malignant development did not appear earlier or in a different way in the animals receiving rhGH from day 6 to 50 than in their appropriate controls. A borderline protective effect to the development of leukemia was seen in the adult group receiving rhGH; in this group antibodies to hGH also developed. We conclude that in this experimental model human therapeutic doses of rhGH do not influence the development of malignancy in the AKR/O mice.
Bechensteen
A G
AG
Department of Paediatrics, Ullevål Hospital, Oslo, Norway.
Halvorsen
S
S
Abdelnoor
M
M
Skottner
A
A
D000818:Animals; D004305:Dose-Response Relationship, Drug; D005260:Female; D013006:Growth Hormone / Q000633:toxicity*; D007942:Leukemia, Experimental / Q000503:physiopathology*; D008223:Lymphoma / Q000503:physiopathology; D008297:Male; D051379:Mice; D008806:Mice, Inbred AKR; D011289:Preleukemia / Q000503:physiopathology*; D011994:Recombinant Proteins / Q000633:toxicity*; D013997:Time Factors; D015430:Weight Gain
D011994:Recombinant Proteins; D013006:Growth Hormone